Our Pipeline

The information below is only presented for the purposes of providing a general overview of our clinical trials. Other than where specifically noted, these compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration.

Wholly-owned U.S. Wholly-owned Collaboration
COMPOUND (Partner)
Phase 1 Phase 2 Phase 3
Or Registration Trial
APPROVED
BRAFTOVI® (encorafenib) capsules +
MEKTOVI® (binimetinib) tablets
Disease State: BRAF-mutant unresectable or metastatic melanoma Target: BRAF + MEK
Approved
    
Encorafenib (Ono, Pierre Fabre) Disease State: Cancer Target: BRAF
Phase 3
   
Binimetinib (Ono, Pierre Fabre) Disease State: Cancer Target: MEK
Phase 3
   
Vitrakvi® (larotrectinib; Bayer AG) Disease State: Cancer Target: PanTrk
Approved
    
Ganovo®** (danoprevir; Roche) Disease State: Hepatitis C Target: NS3 Protease
Approved
    
Selumetinib (AstraZeneca) Disease State: NF1 Target: MEK
Phase 3
   
Tucatinib* (Seattle Genetics) Disease State: Cancer Target: HER-2
Phase 3
   
Ipatasertib (Genentech) Disease State: Cancer Target: AKT
Phase 3
   
Varlitinib (ASLAN) Disease State: Cancer Target: Pan-HER
Phase 3
   
ARRY-797 Disease State: LMNA-related DCM Target: p38
Phase 3
   
LOXO-292* (Eli Lilly) Disease State: Cancer Target: Ret
Phase 3
   
ARRY-382 Disease State: Cancer Target: CSF1R
Phase 2
  
Motolimod (Celgene) Disease State: Cancer Target: TLR
Phase 2
  
Prexasertib (Eli Lilly) Disease State: Cancer Target: Chk1
Phase 2
  
LOXO-195 (Bayer AG) Disease State: Cancer Target: Trk
Phase 1
 
AK-1830 (Asahi Kasei Pharma) Disease State: Inflammation and pain Target: Trk
Phase 1
 
MRTX849 (Mirati Therapeutics) Disease State: Cancer Target: KRAS G12C
Phase 1
 

*Phase 2 registration trials

**Approved in China

LEARN MORE

Find out more about the Phase 3
BEACON CRC trial